Search Results
575 results
Your search is now limited to «Cancer Drugs» expert search.
Zacks.com 03/20/2019 10:43
The acquisition of Tesaro added ovarian cancer drug, Zejula to Glaxo’s portfolio, which will strengthen the latter’s position in the oncology market.
More from Zacks.com:
The drug is derived in part from the black calla lily (arum palaestinum), a native plant found in several regions of the Middle East.
More from Global Banking & Finance Review:
ClinicalTrials.gov 03/20/2019 09:35
Conditions : Cardiovascular Complication; Cardiovascular Insufficiency; Cardiac Complication; Oncologic Complications; Cardiac Insufficiency; Metabolic Disorder; Vascular Disorder; Cardiac Disorder Intervention : Drug: Anti-Cancer Agents Sponsor : Groupe Hospitalier Pitie-Salpetriere Recruiting.
More from ClinicalTrials.gov:
Medindia.com 03/20/2019 07:28
New class of drugs could kill ovarian cancer cells, providing a potential new treatment option for ovarian cancer, according to the University of Manchester researchers.
More from Medindia.com:
PharmaTimes 03/20/2019 05:59
Further data from study will be analysed to support regulatory filing for the drug in endometrial cancer at the end of this year.
More from PharmaTimes:
Fortune 03/19/2019 18:39
The Food and Drug Administration (FDA) delivered a blow to AbbVie, maker of the world’s best-selling drug, Humira, and partner Roche on Tuesday over ongoing studies for a cancer drug.
More from Fortune:
Similar results were obtained for cell migration of lung cancer cells.
More from International Journal of COPD:
Reuters.com 03/19/2019 09:37
The drug is already approved to treat other types of cancer, including chronic lymphocytic leukemia and acute myeloid leukemia.
More from Reuters.com:
STAT 03/19/2019 04:40
Drug shortages jeopardize the lives of children with cancer.
More from STAT:
Technology Org 03/18/2019 17:10
Shrinking tumors The researchers found that the compound slowed cell growth in a variety of Myc-dependent human cancer cells, including models for hepatocellular carcinoma, T-cell acute lymphoblastic leukemia, and Burkitt’s lymphoma.
More from Technology Org:
PR Newswire 03/18/2019 08:45
Patients were then followed for recurrent disease, ductal carcinoma in situ (DCIS), or death for a period of five years after randomisation.
More from PR Newswire:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications